Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) was down 3.4% on Thursday . The stock traded as low as C$1.69 and last traded at C$1.72. Approximately 35,112 shares traded hands during trading, a decline of 30% from the average daily volume of 49,836 shares. The stock had previously closed at C$1.78.
Cardiol Therapeutics Trading Up 2.3 %
The company has a quick ratio of 6.84, a current ratio of 2.39 and a debt-to-equity ratio of 1.07. The firm has a market cap of C$122.99 million, a price-to-earnings ratio of -4.00 and a beta of 0.70. The business's fifty day moving average is C$2.08 and its two-hundred day moving average is C$2.53.
Insider Buying and Selling at Cardiol Therapeutics
In other Cardiol Therapeutics news, Director David Elsley acquired 40,000 shares of Cardiol Therapeutics stock in a transaction on Monday, December 16th. The shares were purchased at an average cost of C$1.88 per share, with a total value of C$75,072.00. Also, Senior Officer Guillermo Torre purchased 17,240 shares of Cardiol Therapeutics stock in a transaction dated Thursday, December 26th. The shares were purchased at an average cost of C$1.81 per share, for a total transaction of C$31,277.77. Over the last ninety days, insiders have acquired 86,140 shares of company stock valued at $161,456. 4.57% of the stock is currently owned by insiders.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Recommended Stories
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
